A Clinical Review on Paroxetine and Emerging Therapies for the Treatment of Vasomotor Symptoms

References

• Pinkerton JV, Santen RJ. Managing vasomotor symptoms in women after cancer. Climacteric. 2019;22(6):544–552. doi:10.1080/13697137.2019.1600501
   PubMed Web of Science ®Google Scholar
• Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric. 2007;10(3):197–214. doi:10.1080/13697130601181486
   PubMed Web of Science ®Google Scholar
• Mittelman-Smith MA, Williams H, Krajewski-Hall SJ, McMullen NT, Rance NE. Role for kisspeptin/neurokinin B/dynorphin (KNDy) neurons in cutaneous vasodilatation and the estrogen modulation of body temperature. Proc Natl Acad Sci U S A. 2012;109(48):19846–19851. doi:10.1073/pnas.1211517109
   PubMed Web of Science ®Google Scholar
• Rance NE, Dacks PA, Mittelman-Smith MA, Romanovsky AA, Krajewski-Hall SJ. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol. 2013;34(3):211–227. doi:10.1016/j.yfrne.2013.07.003
   PubMed Web of Science ®Google Scholar
• Dacks PA, Krajewski SJ, Rance NE. Activation of neurokinin 3 receptors in the median preoptic nucleus decreases core temperature in the rat. Endocrinology. 2011;152(12):4894–4905. doi:10.1210/en.2011-1492
   Web of Science ®Google Scholar
• Jayasena CN, Comninos AN, Stefanopoulou E, et al. Neurokinin B administration induces hot flushes in women. Sci Rep. 2015;5(1). doi:10.1038/srep08466
   Web of Science ®Google Scholar
• Rance NE, Young WS. Hypertrophy and increased gene expression of neurons containing neurokinin-b and substance-p messenger ribonucleic acids in the hypothalami of postmenopausal women. Endocrinology. 1991;128(5):2239–2247. doi:10.1210/endo-128-5-2239
   PubMed Web of Science ®Google Scholar
• Mirkin S, Graham S, Revicki DA, Bender RH, Bernick B, Constantine GD. Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone. Menopause. 2019. doi:10.1097/GME.0000000000001294
   Web of Science ®Google Scholar
• Sarrel P, Portman D, Lefebvre P, et al. Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause. 2015;22(3):260–266. doi:10.1097/GME.0000000000000320
   PubMed Web of Science ®Google Scholar
• Carpenter JS. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 NAMS position statement. Menopause. 2016;23(12):1365.
   Web of Science ®Google Scholar
• Smith T, Sahni S, Thacker HL. Postmenopausal hormone therapy—local and systemic: a pharmacologic perspective. J Clin Pharmacol. 2020;60(S2). doi:10.1002/jcph.1740
   Web of Science ®Google Scholar
• El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation. 2020;142(25). doi:10.1161/CIR.0000000000000912
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Solomon CG. Hormone therapy for postmenopausal women. N Engl J Med. 2020;382(5):446–455. doi:10.1056/nejmcp1714787
   PubMed Web of Science ®Google Scholar
• Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. J Am Med Assoc. 2003;289(21):2827. doi:10.1001/jama.289.21.2827
   PubMed Web of Science ®Google Scholar
• Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. J Am Med Assoc. 2011;305(3):267. doi:10.1001/jama.2010.2016
   PubMed Web of Science ®Google Scholar
• Ensrud KE, Joffe H, Guthrie KA, et al. Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial. Menopause. 2012;19(8):848–855. doi:10.1097/gme.0b013e3182476099
   PubMed Web of Science ®Google Scholar
• Reed SD, Guthrie KA, Joffe H, Shifren JL, Seguin RA, Freeman EW. Sexual function in nondepressed women using escitalopram for vasomotor symptoms: a randomized controlled trial. Obstet Gynecol. 2012;119(3):527–538. doi:10.1097/AOG.0b013e3182475fa4
   Web of Science ®Google Scholar
• Pinkerton JV, Constantine G, Hwang E, Cheng RFJ. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial. Menopause. 2013. doi:10.1097/gme.0b013e31826421a8
   Web of Science ®Google Scholar
• Archer DF, Sturdee DW, Baber R, et al. Menopausal hot flushes and night sweats: where are we now? Climacteric. 2011;14(5):515–528. doi:10.3109/13697137.2011.608596
   PubMed Web of Science ®Google Scholar
• Paroxetine (Brisdelle) for hot flashes. Med Lett Drugs Ther. 2013;55(1428):85–86.
   Web of Science ®Google Scholar
• Capriglione S, Plotti F, Montera R, et al. Role of paroxetine in the management of hot flashes in gynecological cancer survivors: results of the first randomized single-center controlled trial. Gynecol Oncol. 2016;143(3):584–588. doi:10.1016/j.ygyno.2016.10.006
   PubMed Web of Science ®Google Scholar
• Simon JA, Portman DJ, Kaunitz AM, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause. 2013;20(10):1027–1035. doi:10.1097/GME.0b013e3182a66aa7
   PubMed Web of Science ®Google Scholar
• Cristina Castelli M, Bhaskar S, Lippman J. Pharmacokinetic properties of once-daily oral low-dose mesylate salt of paroxetine (ldmp 7.5 mg) following single and multiple doses in healthy postmenopausal women. Clin Ther. 2013;35(6):862–869. doi:10.1016/j.clinthera.2013.05.001
   Web of Science ®Google Scholar
• Stearns V, Johnson MD, Rae J, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95(23):1758–1764. doi:10.1093/jnci/djg108
   PubMed Web of Science ®Google Scholar
• Stearns V, Isaacs C, Rowland J, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil®) in controlling hot flashes in breast cancer survivors. Ann Oncol. 2000;11(1):17–22. doi:10.1023/A:1008382706068
   PubMed Web of Science ®Google Scholar
• Weitzner MA, Moncello J, Jacobsen PB, Minton S. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage. 2002;23(4):337–345. doi:10.1016/S0885-3924(02)00379-2
   PubMed Web of Science ®Google Scholar
• Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol. 2005;23(28):6919–6930. doi:10.1200/JCO.2005.10.081
   PubMed Web of Science ®Google Scholar
• Carroll DG, Lisenby KM, Carter TL. Critical appraisal of paroxetine for the treatment of vasomotor symptoms. Int J Womens Health. 2015;615. doi:10.2147/IJWH.S50804
   Google Scholar
• Pinkerton JV, Joffe H, Kazempour K, Mekonnen H, Bhaskar S, Lippman J. Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause. Menopause. 2015;22(1):50–58. doi:10.1097/GME.0000000000000311
   PubMed Web of Science ®Google Scholar
• Schow DA, Renfer LG, Rozanski TA, Thompson IM. Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J. 1998;91(9):855–857. doi:10.1097/00007611-199809000-00010
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Barton DL, Carpenter LA, et al. Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clin Proc. 2004;79(10):1247–1251. doi:10.4065/79.10.1247
   PubMed Web of Science ®Google Scholar
• Haney EM, Warden SJ, Bliziotes MM. Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone. 2010;46(1):13–17. doi:10.1016/j.bone.2009.07.083
   PubMed Web of Science ®Google Scholar
• Sheu YH, Lanteigne A, Stürmer T, Pate V, Azrael D, Miller M. SSRI use and risk of fractures among perimenopausal women without mental disorders. Inj Prev. 2015;21(6):397–403. doi:10.1136/injuryprev-2014-041483
   PubMed Web of Science ®Google Scholar
• Carris N, Kutner S, Reilly-Rogers S. New pharmacological therapies for vasomotor symptom management: focus on bazedoxifene/conjugated estrogens and paroxetine mesylate. Ann Pharmacother. 2014;48(10):1343–1349. doi:10.1177/1060028014543099
   Web of Science ®Google Scholar
• Portman DJ, Kaunitz AM, Kazempour K, Mekonnen H, Bhaskar S, Lippman J. Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause. Menopause. 2014;21(10):1082–1090. doi:10.1097/gme.0000000000000210
   Web of Science ®Google Scholar
• Shrestha P, Fariba K, Abdijadid S. Paroxetine. In: StatPearls. Tresure Island (FL): StatPearls Publishing;2018.
   Google Scholar
• Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97(1):30–39. doi:10.1093/jnci/dji005
   PubMed Web of Science ®Google Scholar
• Aubert RE, Stanek EJ, Yao J, et al. Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. J Clin Oncol. 2009;27(15_suppl):CRA508–CRA508. doi:10.1200/jco.2009.27.15_suppl.cra508
   Google Scholar
• Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 2010;340:c693–c693. doi:10.1136/bmj.c693
   PubMed Web of Science ®Google Scholar
• De Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013;16(3):316–337. doi:10.3109/13697137.2013.795683
   PubMed Web of Science ®Google Scholar
• Cho YW, Kim EJ, Nyiramana MM, et al. Paroxetine induces apoptosis of human breast cancer MCF-7 cells through Ca 2+ -and p38 MAP kinase-dependent ROS generation. Cancers. 2019;11(1):64. doi:10.3390/cancers11010064
   Web of Science ®Google Scholar
• Kowalska M, Nowaczyk J, Fijałkowski Ł, Nowaczyk A. Paroxetine—overview of the molecular mechanisms of action. Int J Mol Sci. 2021;22(4):1662. doi:10.3390/ijms22041662
   PubMed Web of Science ®Google Scholar
• Coelingh Bennink HJT, Holinka CF, Diczfalusy E. Estetrol review: profile and potential clinical applications. Climacteric. 2008;11(sup1):47–58. doi:10.1080/13697130802073425
   PubMed Web of Science ®Google Scholar
• Coelingh Bennink HJT, Verhoeven C, Zimmerman Y, Visser M, Foidart JM, Gemzell-Danielsson K. Clinical effects of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women. Maturitas. 2016;91:93–100. doi:10.1016/j.maturitas.2016.06.017
   PubMed Web of Science ®Google Scholar
• Reame NK. Estetrol for menopause symptoms: the cinderella of estrogens or just another fairy tale? Menopause. 2020;27(8):841–843. doi:10.1097/GME.0000000000001601
   Web of Science ®Google Scholar
• Visser M, Foidart JM, Coelingh Bennink HJT. In vitro effects of estetrol on receptor binding, drug targets and human liver cell metabolism. Climacteric. 2008;11(sup1):64–68. doi:10.1080/13697130802050340
   PubMed Web of Science ®Google Scholar
• Hammond GL, Hogeveen KN, Visser M, Coelingh Bennink HJT. Estetrol does not bind sex hormone binding globulin or increase its production by human HepG2 cells. Climacteric. 2008;11(sup1):41–46. doi:10.1080/13697130701851814
   PubMed Web of Science ®Google Scholar
• Gaspard U, Taziaux M, Mawet M, et al. A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety. Menopause. 2020;27(8):848–857. doi:10.1097/GME.0000000000001561
   PubMed Web of Science ®Google Scholar
• Kim WO, Kil HK, Yoon KB, Yoo JH. Treatment of generalized hyperhidrosis with oxybutynin in postmenopausal patients. Acta Derm Venereol. 2010;90(3):291–293. doi:10.2340/00015555-0828
   Web of Science ®Google Scholar
• Simon JA, Gaines T, LaGuardia KD, et al. Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial. Menopause. 2016;23(11):1214–1221. doi:10.1097/GME.0000000000000773
   PubMed Web of Science ®Google Scholar
• Leon-Ferre RA, Novotny PJ, Wolfe EG, et al. Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603). JNCI Cancer Spectrum. 2020;4(1). doi:10.1093/jncics/pkz088
   Web of Science ®Google Scholar
• Fick D, Semla T, Beizer J, et al. American geriatrics society updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012. doi:10.1111/j.1532-5415.2012.03923.x
   Web of Science ®Google Scholar
• Duong V, Iwamoto A, Pennycuff J, Kudish B, Iglesia C. A systematic review of neurocognitive dysfunction with overactive bladder medications. Int Urogynecol J. 2021;32(10):2693–2702. doi:10.1007/s00192-021-04909-5
   Web of Science ®Google Scholar
• Lehman MN, Coolen LM, Goodman RL. Minireview: kisspeptin/neurokinin B/dynorphin (KNDy) cells of the arcuate nucleus: a central node in the control of gonadotropin-releasing hormone secretion. Endocrinology. 2010;151(8):3479–3489. doi:10.1210/en.2010-0022
   PubMed Web of Science ®Google Scholar
• Prague JK, Roberts RE, Comninos AN, et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10081):1809–1820. doi:10.1016/S0140-6736(17)30823-1
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Manson JE, Hohensee C, et al. Association of genetic variation in the tachykinin receptor 3 locus with hot flashes and night sweats in the women’s health initiative study. Menopause. 2017;24(3):252–261. doi:10.1097/GME.0000000000000763
   PubMed Web of Science ®Google Scholar
• Depypere H, Lademacher C, Siddiqui E, Fraser GL. Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opin Investig Drugs. 2021;30(7):681–694. doi:10.1080/13543784.2021.1893305
   PubMed Web of Science ®Google Scholar
• Santoro N, Waldbaum A, Lederman S, et al. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause. 2020;27(12):1350–1356. doi:10.1097/GME.0000000000001621
   PubMed Web of Science ®Google Scholar